The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.
Seong Hee KangMinjong LeeMoon-Young KimJun Hyeok LeeBaek Gyu JunTae Suk KimDae Hee ChoiKi Tae SukYoung Don KimGab Jin CheonDong Joon KimSoon Koo BaikPublished in: Hepatology international (2021)
NSBB therapy was associated with longer survival in PP and SP groups who had an advanced stage of cirrhosis. Moreover, low-dose NSBB exhibited a better benefit than a standard-titrated high-dose NSBB with better tolerability.